Sugi Predict

Sugi Predict / Compounds / SCHEMBL23218188

SCHEMBL23218188

SCHEMBL23218188

CCOC(=O)Cc1ccc(OC)cc1OCc1c(-c2ccc(F)cc2)oc2ccc(-c3cccc(CN)c3)cc12

nearest known ligand 0.44

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ANO1 Q5XXA6 9/20 0.44
▸ CFD P00746 2/20 0.42
▸ KDM4E B2RXH2 2/20 0.41
▸ ALDH1A1 P00352 2/20 0.41
▸ HPGD P15428 2/20 0.41
▸ PLG P00747 1/20 0.41
▸ PLAU P00749 1/20 0.41
▸ F11 P03951 1/20 0.41
▸ KLKB1 P03952 1/20 0.41
▸ F7 P08709 1/20 0.41
▸ TPSB2 P20231 1/20 0.41
▸ MAPT P10636 3/20 0.40
▸ GAA P10253 1/20 0.39
▸ MEN1 O00255 1/20 0.39
▸ KMT2A Q03164 1/20 0.39
▸ MTNR1A P48039 2/20 0.38
▸ MTNR1B P49286 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29852537 1.00 ANO1 (0.44) ANO1CFDKDM4EALDH1A1HPGD
SCHEMBL29852924 0.91 CFD (0.42) ANO1CFDKDM4EALDH1A1HPGD
SCHEMBL29593277 0.91 CFD (0.52) ANO1CFDPLGPLAUF11
SCHEMBL23219174 0.91 CFD (0.42) ANO1CFDKDM4EALDH1A1HPGD
SCHEMBL23218451 0.91 CFD (0.52) ANO1CFDPLGPLAUF11
SCHEMBL23218874 0.91 CFD (0.51) ANO1CFDPLGPLAUF11
SCHEMBL29853184 0.91 CFD (0.51) ANO1CFDPLGPLAUF11
SCHEMBL23218533 0.89 CFD (0.43) ANO1CFDKDM4EALDH1A1HPGD
SCHEMBL29852791 0.89 CFD (0.43) ANO1CFDKDM4EALDH1A1HPGD
SCHEMBL23218602 0.88 CFD (0.41) ANO1CFDKDM4EALDH1A1HPGD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12558341-B2 Oral complement factor D inhibitors BIOCRYST PHARMACEUTICALS, INC. (US) 2026-02-24 — — US disclosed
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION 2025-06-12 — — US disclosed
CN-114502168-A Oral complement factor D inhibitors 拜奥克里斯特制药公司 2022-05-13 — — CN disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
WO-2021072198-A1 ORAL COMPLEMENT FACTOR D INHIBITORS BIOCRYST PHARMACEUTICALS, INC. (US) 2021-04-15 — — WO disclosed
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY ACADIA PHARMACEUTICALS INC. 2016-12-15 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160361275-A1 SUBSTITUTED PHENETHYLAMINES WITH SEROTONINERGIC AND/OR NOREPINEPHRINERGIC ACTIVITY SLC6A4, HTR4, GPR34 ANO1 1596/4885CFD 4300/4885KDM4E 1720/4885
US-12558341-B2 Oral complement factor D inhibitors CFD, CFH, CFB ANO1 2994/4885CFD 1/4885KDM4E 4172/4885
US-20250186391-A1 ORAL COMPLEMENT FACTOR D INHIBITORS CFD, CFH, CFB ANO1 3834/4885CFD 1/4885KDM4E 4491/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.